Literature DB >> 30992190

Inducing Fat to Feed a Natural Killer of Malignancy.

Benedetta Rambaldi1, Rizwan Romee2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30992190      PMCID： PMC6520461          DOI： 10.1016/j.ymthe.2019.04.005

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

1.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.

Authors:  Run Xiao; Anthony G Mansour; Wei Huang; Logan A Chrislip; Ryan K Wilkins; Nicholas J Queen; Youssef Youssef; Hsiaoyin C Mao; Michael A Caligiuri; Lei Cao
Journal:  Mol Ther       Date:  2019-02-16       Impact factor: 11.454

3.  Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.

Authors:  Peter R Rhode; Jack O Egan; Wenxin Xu; Hao Hong; Gabriela M Webb; Xiaoyue Chen; Bai Liu; Xiaoyun Zhu; Jinghai Wen; Lijing You; Lin Kong; Ana C Edwards; Kaiping Han; Sixiang Shi; Sarah Alter; Jonah B Sacha; Emily K Jeng; Weibo Cai; Hing C Wong
Journal:  Cancer Immunol Res       Date:  2015-10-28       Impact factor: 11.151

4.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Authors:  Kevin C Conlon; Enrico Lugli; Hugh C Welles; Steven A Rosenberg; Antonio Tito Fojo; John C Morris; Thomas A Fleisher; Sigrid P Dubois; Liyanage P Perera; Donn M Stewart; Carolyn K Goldman; Bonita R Bryant; Jean M Decker; Jing Chen; Tat'Yana A Worthy; William D Figg; Cody J Peer; Michael C Sneller; H Clifford Lane; Jason L Yovandich; Stephen P Creekmore; Mario Roederer; Thomas A Waldmann
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

Review 5.  CAR T cell immunotherapy for human cancer.

Authors:  Carl H June; Roddy S O'Connor; Omkar U Kawalekar; Saba Ghassemi; Michael C Milone
Journal:  Science       Date:  2018-03-23       Impact factor: 47.728

6.  Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation.

Authors:  Spencer W Stonier; Lisa J Ma; Eliseo F Castillo; Kimberly S Schluns
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

Review 7.  Natural killer cell-mediated immunosurveillance of human cancer.

Authors:  Karl-Johan Malmberg; Mattias Carlsten; Andreas Björklund; Ebba Sohlberg; Yenan T Bryceson; Hans-Gustaf Ljunggren
Journal:  Semin Immunol       Date:  2017-09-06       Impact factor: 11.130

8.  First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Authors:  Rizwan Romee; Sarah Cooley; Melissa M Berrien-Elliott; Peter Westervelt; Michael R Verneris; John E Wagner; Daniel J Weisdorf; Bruce R Blazar; Celalettin Ustun; Todd E DeFor; Sithara Vivek; Lindsey Peck; John F DiPersio; Amanda F Cashen; Rachel Kyllo; Amy Musiek; András Schaffer; Milan J Anadkat; Ilana Rosman; Daniel Miller; Jack O Egan; Emily K Jeng; Amy Rock; Hing C Wong; Todd A Fehniger; Jeffrey S Miller
Journal:  Blood       Date:  2018-02-20       Impact factor: 25.476

9.  Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.

Authors:  T A Fehniger; K Suzuki; A Ponnappan; J B VanDeusen; M A Cooper; S M Florea; A G Freud; M L Robinson; J Durbin; M A Caligiuri
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

10.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Authors:  Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal
Journal:  Cancer       Date:  2018-05-22       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.